Bacteria

34 teams from seven departments are addressing the antibiotic resistance challenge with multidisciplinary approaches to characterize and prevent the emergence and the dissemination of antibiotic resistance genes and resistant bacteria and to develop new drugs and alternative strategies to fight bacterial infections.

|

Charles Baroud - Physical Microfluidics and Bioengineering 

In this group, the scientists are using microfluidic tools and imaging to study the emergence of antibiotic resistance at the scale of individual cells.

See the Website

Frederic Barras - Stress adaptation and metabolism in enterobacteria

Understanding molecular, metabolic and physiological mechanisms of antibiotic activity and of phenotypic resistance.

See the Website

Gregory Batt - InBio: Experimental and Computational Methods for Modeling Cellular Processes

This unit is developing models to characterize individual and collective antibiotic resistance to -lactams, together with algorithms and experimental platforms for their automated and efficient calibrations.

See the Website

Christophe Beloin - Genetics of Biofilms

This unit aims at understanding the molecular mechanisms beyond the extreme tolerance of biofilms towards antibiotics and the link between this tolerance and evolution of resistance in order to identify novel strategies to fight biofilm-associated infections and to reduce emergence of antibiotic resistance.

See the Website

David Bikard - Synthetic Biology

The Synthetic Biology group is developing CRISPR tools to study and fight antibiotic resistant bacteria.

See the Website

Sylvain Brisse - Biodiversity and Epidemiology of Bacterial Pathogens 

The scientists use genomics and bioinformatics to understand the global dissemination of multidrug resistance strains and they provide to the community, unified nomenclatures (“genomic taxonomies of strains”) that allow global communication on strain subtypes and their tracking across time, geography and activity sectors (“One Health”). 

See the Website

Carmen Buchrieser - Biology of Intracellular Bacteria

This unit is investigating how immunological responses, metabolic signalling, metabolic fluxes, and subcellular architecture of host cells are modified during infection by intracellular pathogens using Legionella pneumophila as a model. This knowledge will be used to identify immunometabolic drugs to tackle infection and to target host pathways instead of the pathogen.

SEE THE WEBSITE

Nienke Buddelmeijer - Biology and Genetics of Bacterial Cell Wall

Lipoprotein modification in bacteria: a novel target for antibiotics

See the Website

Dominique Clermont - Biological Resources Center

Screening for metabolites potentially usable as new antimicrobials and Study of the history and evolution of resistance in ESKAP pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa) are expanding the bacterial landscape of innovative solutions to combating AMR today.

See the Website

Laurent Debarbieux - Molecular Biology of Gene in Extremophiles

Using animals models, this group is elucidating the mechanisms supporting the efficacy of bacteriophages for treating infections caused by AMR bacteria.

See the Website

Caroline Demangel - Immunobiology of Infection

This unit aims to determine whether host-derived lipids may function as natural antibiotics, and can be considered as effectors of the innate immune system.

See the Website

Hilde De-Reuse - Helicobacter Pathogenesis

Understanding the mode of action of existing medications and investigating new targets and molecules to fight infection by Helicobacter pylori, a priority pathogen for AMR that is responsible for 800,000 deaths every year worldwide.

See the Website

Guillaume Dumenil - Pathogenesis of vascular infections

An anti-virulence strategy based on the inhibition of type IV pili is efficient on various bacteria including antibiotic resistant Neisseria gonorrhoeae.

See the Website

Bruno Dupuy - Pathogenesis of Bacterial Anaerobes

Development of new therapeutic potentials against Clostridium difficile.

See the Website

Olivier Dussurget - Yersinia

Design and synthesis of NAD kinase inhibitors as novel antibacterial agents.

See the Website

Jost Enninga - Dynamics of Host-Pathogen Interactions

Using an interdisciplinary research approach, this unit investigates how bacterial pathogens subvert host cells to reach intracellular niches to escape from antimicrobials and the host immune response. 

See the Website

Jean-Marc Ghigo - Genetics of Biofilms

Identification of functions promoting the rise and fall of antibiotic-tolerant bacterial biofilms.

See thge website

Philippe Glaser - Ecology and Evolution of Antibiotics Resistance

This unit is addressing a major threat in antibiotic resistance: the global dissemination of multidrug resistant (MDR) lineages and of antibiotic resistant genes. The scientists are focusing on carbapenemase producing enterobacteriaceae which are considered by WHO as “critical” priority pathogens.

See thge website

Ivo Gomperts-Boneca - Biology and Genetics of Bacterial Cell Wall

Searching for new therapeutic strategies targeting the assembly of the cell wall of bacteria.

See the website

Simonetta Gribaldo - Evolutionary Biology of the Microbial Cell

By studying fundamental cellular processes in bacteria and archaea, the researchers can discover novel targets for antimicrobial agents.

See the website

Didier Guillemot - Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases

This team aims at decipheing dynamic causal links between human contacts, bacterial intrinsic transmission capacities for resistant gene vectorization, factors affecting human and environmental microbiota disruption, and the burden of antibiotic resistance.

See the website

Melanie Hamon - Chromatin and Infection

The work of this unit focuses on bacteria-host interactions, with the aim to target host mechanisms essential for bacterial growth and find alternatives to current direct-acting anti-bacterial drugs.

See the website

Molly Ingersoll - Mucosal Inflammation and Immunology

This group is developing non-antibiotic based immunomodulatory therapeutic approaches to combat multidrug resistant urinary tract infections.

See the website

Daniel Ladant - Biochemistry of Macromolecular Interactions

The goal of this unit is to exploit an innovative and robust target-based in vivo screening pipeline based on a robust bacterial two hybrid screening technology (BACTH) to identify small-molecules able to block the assembly of bacterial cell division machinery. 

See the website

Marc Lecuit - Biology of Infection

The researchers follow an interdisciplinary approach to understand Listeria biology, its pathogenic potential and saprophytic life, and its dynamics within and outside the host.

See the website

Emmanuel Lemichez - Bacterial Toxins

This team pursues novel promising approaches aiming at fighting toxi-infections through development of chemical compounds acting directly on host components to confer to cells resistance properties to the arsenal of pathogens and stimulate innate immune responses.

See the website

Giulia Manina - Microbial Individuality and Infection

Drug enhancers that target phenotypic variation to accelerate treatment and prevent resistance.

See the website

Didier Mazel - Bacterial Genome Plasticity

This team fights resistance from both side: understanding the genetics behind its development and proposing alternate antimicrobial strategies.

See the website

Javier Pizarro-Cerda - Yersinia

This unit investigates both novel compounds against essential bacterial genes as well as novel bactericidal molecules against Gram-positive pathogens.

See the website

Eduardo Rocha - Evolutionary Microbial Genomics

This lab uses bioinformatics, genomics, metagenomics, and experimental approaches to understand how mobile genetic elements drive bacterial adaptation by way of horizontal gene transfer, including the acquisition of antibiotic resistance genes. 

See the website

Brice Sperandio - Molecular Microbial Pathogenesis

Deciphering the regulation of human innate antimicrobial mechanisms to develop innovative immuno-stimulatory molecules.

See the website

Lhousseine Touqui - Group: Cystic Fibrosis and Bronchial Diseases

The use of antimicrobial peptides (AMPs) combined with nanoparticles (NPs) to fight multi-resistant bacteria.

See the website

Sven Van-Teeffelen - Microbial Morphogenesis and Growth

This lab works on the ability of cells to protect their mechanical integrity against cell-wall damage caused by antibiotics and other stresses, largely using single-cell time-lapse microscopy.

See the website

Francois-Xavier Weill - Enteric Bacterial Pathogens

Thanks to a unique of historical bacterial isolates and collaboration with clinical laboratories, food and veterinary agencies at national or international level, these scientists can carry out large-scale genomic studies, to determine population structures, phylogeographic patterns, and genetic evolution of antibiotic resistant enteric bacterial populations.

See the website

Back to top